Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study

Shoemaker, K., Soboleva, K., Branche, A., Shankaran, S., Theodore, D. A., Bari, M., Ezeh, V., Green, J., Kelly, E., Lan, D., Olsson, U., Saminathan, S., Shankar, N. K., Villegas, B., Villafana, T., Falsey, A. R., & Sobieszczyk, M. E. (2024). Long-Term Safety and Immunogenicity of AZD1222 (ChAdOx1 nCoV-19): 2-Year Follow-Up from a Phase 3 Study. Vaccines, 12(8), 883. https://doi.org/10.3390/vaccines12080883
Authors:
Kathryn Shoemaker
Karina Soboleva
Angela Branche
Shivanjali Shankaran
Deborah A Theodore
Muhammad Bari
Victor Ezeh
Justin Green
Elizabeth Kelly
Dongmei Lan
Urban Olsson
Senthilkumar Saminathan
Nirmal Kumar Shankar
Berta Villegas
Tonya Villafana
Ann R Falsey
Magdalena E Sobieszczyk
Affiliated Authors:
Deborah A Theodore
Magdalena E Sobieszczyk
Author Keywords:
azd1222 (chadox1 ncov-19)
covid-19
long-term safety
sars-cov-2
humoral immunogenicity
covid-19 vaccine
omicron variant
Publication Type:
Article
Unique ID:
10.3390/vaccines12080883
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: